Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9% - Here's Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares fell 4.9% during mid-day trading on Thursday . The stock traded as low as $19.86 and last traded at $20.07. 24,946 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 268,096 shares. The stock had previously closed at $21.09.

Wall Street Analyst Weigh In

DNTH has been the topic of a number of recent research reports. William Blair assumed coverage on shares of Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating on the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Robert W. Baird cut their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $53.00.

Dianthus Therapeutics Trading Down 2.7%

The stock has a market cap of $645.13 million, a P/E ratio of -6.97 and a beta of 1.38. The company has a 50 day simple moving average of $18.68 and a 200 day simple moving average of $20.36.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. As a group, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in Dianthus Therapeutics in the fourth quarter valued at about $33,000. US Bancorp DE grew its holdings in shares of Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after purchasing an additional 1,510 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Dianthus Therapeutics in the fourth quarter worth $59,000. GAMMA Investing LLC raised its stake in shares of Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after acquiring an additional 3,758 shares in the last quarter. Finally, AlphaQuest LLC raised its stake in shares of Dianthus Therapeutics by 273.1% during the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock worth $91,000 after acquiring an additional 3,072 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.